Research programme: peptide therapeutics - BioLineRx/Compugen

Drug Profile

Research programme: peptide therapeutics - BioLineRx/Compugen

Alternative Names: BL-7060; BL-8010; CGEN-25017; CGEN-855; CGEN-856; EDP 29; EDP 30

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Compugen
  • Developer BioLineRx
  • Class Peptides
  • Mechanism of Action Angiogenesis inhibitors; Angiopoietin inhibitors; G protein-coupled receptor agonists; RXFP1 protein stimulants; TIE 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Myocardial infarction
  • Discontinued Retinal disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Myocardial-infarction in Israel
  • 01 Mar 2013 Discontinued - Preclinical for Retinal disorders in Israel (unspecified route)
  • 13 Dec 2011 Preclinical trials in Myocardial infarction in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top